R
Richard W.M. van der Maazen
Researcher at Radboud University Nijmegen
Publications - 54
Citations - 3081
Richard W.M. van der Maazen is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Radiation therapy & Procarbazine. The author has an hindex of 19, co-authored 45 publications receiving 2628 citations. Previous affiliations of Richard W.M. van der Maazen include Utrecht University & Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Michael Schaapveld,Berthe M.P. Aleman,Anna M. van Eggermond,Cecile P.M. Janus,Augustinus D.G. Krol,Richard W.M. van der Maazen,Judith M. Roesink,John M. M. Raemaekers,Jan de Boer,Josée M. Zijlstra,Gustaaf W. van Imhoff,Eefke Petersen,Philip Poortmans,Max Beijert,Marnix L.M. Lybeert,Ina Mulder,Otto Visser,Marieke W. J. Louwman,Inge M. Krul,Pieternella J. Lugtenburg,Flora E. van Leeuwen +20 more
TL;DR: The risk of second solid cancers did not appear to be lower among patients treated in the most recent calendar period studied (1989-2000) than among those treated in earlier periods.
Journal ArticleDOI
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma : Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
Marc André,Theodore Girinsky,Massimo Federico,Oumedaly Reman,Catherine Fortpied,Manuel Gotti,Olivier Casasnovas,Pauline Brice,Richard W.M. van der Maazen,Alessandro Re,Veronique Edeline,Christophe Fermé,Gustaaf W. van Imhoff,Francesco Merli,Reda Bouabdallah,Catherine Sebban,Lena Specht,Aspasia Stamatoullas,Richard Delarue,Valeria Fiaccadori,Monica Bellei,Tiana Raveloarivahy,Annibale Versari,Martin Hutchings,Michel Meignan,John M. M. Raemaekers +25 more
TL;DR: In stage I and II HL, PET response after two cycles of ABVD allows for early treatment adaptation when ePET is positive, and switching to BEACOPPesc + INRT significantly improved 5-year PFS.
Journal ArticleDOI
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines
Theodore Girinsky,Richard W.M. van der Maazen,Lena Specht,Berthe M.P. Aleman,Philip Poortmans,Yolande Lievens,Paul Meijnders,Mithra Ghalibafian,J.H. Meerwaldt,Evert M. Noordijk +9 more
TL;DR: The concept of involved-node radiotherapy (INRT) described here is the first attempt to reduce the size of radiation fields compared to the classic involved fields used in adult patients.
Journal ArticleDOI
Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial
John M. M. Raemaekers,Marc André,Massimo Federico,Theodore Girinsky,Reman Oumedaly,Ercole Brusamolino,Pauline Brice,Christophe Fermé,Richard W.M. van der Maazen,Manuel Gotti,Reda Bouabdallah,Catherine Sebban,Yolande Lievens,Allessandro Re,Aspasia Stamatoullas,F. Morschhauser,Pieternella J. Lugtenburg,Elisabetta Abruzzese,Pierre Olivier,Rene-Olivier Casasnovas,Gustaaf W. van Imhoff,Tiana Raveloarivahy,Monica Bellei,Thierry Van der Borght,Stéphane Bardet,Annibale Versari,Martin Hutchings,Michel Meignan,Catherine Fortpied +28 more
TL;DR: Combined-modality treatment resulted in fewer early progressions in clinical stage I/II HL, although early outcome was excellent in both arms.
Journal ArticleDOI
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma
Frederika A. van Nimwegen,Michael Schaapveld,D Cutter,Cecile P.M. Janus,Augustinus D.G. Krol,Michael Hauptmann,Karen Kooijman,Judith M. Roesink,Richard W.M. van der Maazen,Sarah C. Darby,B.M.P. Aleman,Flora E. van Leeuwen +11 more
TL;DR: The linear radiation dose-response relationship identified can be used to predictCHD risk for future HL patients and survivors and Appropriate early management of CHD risk factors and stimulation of physical activity may reduce CHDrisk in HL survivors.